microdosing glp-1 agonists Drugs: What To Know Dr. Blum and our patient

Pooyandjoo, M

Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity

A lower dose of liposomal glutathione often provides better results than a massive dose of standard powder that the body cannot absorb

Not all GLP-1s are approved for obesity treatment, and this analysis includes all FDA-approved GLP-1s, including those approved for obesity (Saxenda, Weogvy, Zepbound) as well as those approved for type 2 diabetes (see Table 1)

Once inside the mitochondrial matrix, these fatty acids undergo beta-oxidation, a process that chops them into smaller acetyl-CoA molecules